ロード中...
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Consensus guidelines recommend dopamine agonists (DAs) as the mainstay treatment for prolactinomas. In most patients, DAs achieve tumor shrinkage and normoprolactinemia at well tolerated doses. However, primary or, less often, secondary resistance to DAs may be also encountered representing challeng...
保存先:
| 出版年: | Pituitary |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6957547/ https://ncbi.nlm.nih.gov/pubmed/31522358 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11102-019-00987-3 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|